Difficulty: Medium
Average Score: 67%
Practice
Myasthenia Gravis is caused by blocking the effect of
Correct answer
C
Rationale
Myasthenia Gravis is caused by blocking the effect of Acetylcholine. Acetylcholine is a neurotransmitter responsible for transmitting signals between nerve cells and muscle cells. In Myasthenia Gravis, the immune system mistakenly attacks acetylcholine receptors at the neuromuscular junction, leading to muscle weakness and fatigue.
Option A, Dopamine, is not the correct answer because dopamine is not directly involved in the neuromuscular junction or the pathophysiology of Myasthenia Gravis. Option B, Norepinephrine, is also incorrect as it is not the neurotransmitter primarily affected in this condition. Option D, Epinephrine, is not the cause of Myasthenia Gravis either.
Understanding the role of acetylcholine in neuromuscular transmission is crucial for healthcare professionals, especially pharmacologists, as it influences the choice of medications used to treat Myasthenia Gravis. By knowing the correct neurotransmitter involved, healthcare providers can select appropriate drugs like acetylcholinesterase inhibitors to improve muscle strength and function in patients with this condition. This knowledge is essential for safe and effective pharmacological management across different age groups affected by Myasthenia Gravis.
Option A, Dopamine, is not the correct answer because dopamine is not directly involved in the neuromuscular junction or the pathophysiology of Myasthenia Gravis. Option B, Norepinephrine, is also incorrect as it is not the neurotransmitter primarily affected in this condition. Option D, Epinephrine, is not the cause of Myasthenia Gravis either.
Understanding the role of acetylcholine in neuromuscular transmission is crucial for healthcare professionals, especially pharmacologists, as it influences the choice of medications used to treat Myasthenia Gravis. By knowing the correct neurotransmitter involved, healthcare providers can select appropriate drugs like acetylcholinesterase inhibitors to improve muscle strength and function in patients with this condition. This knowledge is essential for safe and effective pharmacological management across different age groups affected by Myasthenia Gravis.